Journal of Clinical Medicine

Journal Browser

► Journal Browser

Non-small Cell Lung Cancer: Current Updates and Perspectives

Share This Special Issue

Special Issue Information

Dear Colleagues,

Lung cancer (LC) is the leading cause of cancer deaths in the world, with a less than 20% 5-year survival rate; this is due to diagnoses in the late stage of the disease. Although tissue biopsy remains the most widely used method for categorizing tumors and therapeutic decisions, liquid biopsy (LB), as a new method of observing tumor genetics and tumor dynamics, has also attracted remarkable interest among the oncology community.

The purpose of this Special Issue, “Non-Small Cell Lung Cancer: Current Updates and Perspectives” is to highlight 1) new personalized medicine methods for improving the diagnosis, treatment, and prognosis of NSCLC patients; 2) new technologies and assays that can achieve optimal sensitivity for the early detection of minimal residual disease (MRD) in NSCLC patients; 3) the importance of liquid biopsy as a new tool in therapeutic decision making; and 4) the rapid development of technology and drugs.

Dr. Athina N. Markou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

non-small cell lung cancer (NSCLC)
liquid biopsy
cell-free DNA (cfDNA)
minimal residual disease (MRD)
circulating tumor cells (CTCs)
heterogeneity
epithelial–mesenchymal transition (EMT)
tyrosine kinase inhibitor (TKI)

Published Papers (1 paper)

Research

9 pages, 2371 KiB

Open AccessArticle

The Prognostic Value of Positron Emission Tomography/Computed Tomography in Clinical Stage I Lung Cancer Patients: A Propensity-Match Analysis

by Ya-Fu Cheng, Jing-Yang Huang, Ching-Hsiung Lin, Sheng-Hao Lin and Bing-Yen Wang

J. Clin. Med. 2024, 13(8), 2416; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm13082416 - 21 Apr 2024

Viewed by 370

Abstract

Background: The application of positron emission tomography/computed tomography (PET/CT) helps provide accurate clinical staging for lung cancer patients. However, the effects and trends in early-stage lung cancer remain unclear. The aim of this study was to compare differences between clinical stage I lung cancer patients who received PET/CT for staging and those who did not. Methods: Data were obtained from the Taiwan Society of Cancer Registry. There were 6587 clinical stage I lung cancer patients between 2009 and 2014 analyzed in this study. We compared the characteristics of the PET/CT and no PET/CT groups. After propensity score matching, it resulted in both groups having 2649 patients. We measured the overall survival rates of all clinical stage I lung cancer patients and the overall survival rates of patients with PET/CT and without PET/CT. Results: The 1-, 3-, and 5-year survival rates of all clinical stage I lung cancer patients were 97.2%, 88.2%, and 79.0%, respectively. Patients with a larger tumor size tended to receive PET/CT for staging (stage Ib: 38.25% vs. 27.82%, p < 0.0001) and a larger resection (lobectomy: 74.62% vs. 66.61%, p < 0.0001). The 5-year survival rates were 79.8% in the PET/CT group and 78.2% in the no PET/CT group after propensity score matching (p = 0.6528). Conclusions: For clinical stage I lung cancer in Taiwan, patients with larger tumor sizes tend to have PET/CT for staging. Although PET/CT provided more precise clinical staging, these patients still received larger resections and had more pathological migration. However, there was no overall survival rate benefit after PET/CT. Full article

(This article belongs to the Special Issue Non-small Cell Lung Cancer: Current Updates and Perspectives)

► Show Figures